Jennifer Bright - 06 Jul 2022 Form 3 Insider Report for BIOLASE, INC (BIOLQ)

Role
Chief Financial Officer
Signature
/s/ Michael C. Carroll, attorney-in-fact for Jennifer Bright
Issuer symbol
BIOLQ
Transactions as of
06 Jul 2022
Net transactions value
$0
Form type
3
Filing time
14 Jul 2022, 18:09:43 UTC
Next filing
12 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BIOL Common Stock 160 06 Jul 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BIOL Restricted Stock Unit 06 Jul 2022 Common Stock 600 Direct F1, F2
holding BIOL Restricted Stock Unit 06 Jul 2022 Common Stock 3,600 Direct F2, F3
holding BIOL Restricted Stock Unit 06 Jul 2022 Common Stock 13,500 Direct F2, F4
holding BIOL Stock Option (right to buy) 06 Jul 2022 Common Stock 800 $32.25 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock unit award vests as to 200 shares on each of February 15, 2023, February 15, 2024, and February 15, 2025, subject to the Reporting Person's continued service with the Company.
F2 At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent.
F3 The restricted stock unit award vests as to 1,800 shares on each of August 10, 2022 and August 10, 2023, subject to the Reporting Person's continued service with the Company.
F4 The restricted stock unit award vests in accordance with performance criteria established by the Compensation Committee of the Company, subject to the Reporting Person's continued service with the Company.
F5 The stock option vests immediately as to 201 shares, and the remainder vests ratably over a 36-month period, commencing on March 15, 2022, subject to the Reporting Person's continued service with the Company.